Studies of the Antitumor Activity of Iodacetate in the Liposomal Form.
Dokl Biochem Biophys
; 507(1): 278-282, 2022 Dec.
Article
in En
| MEDLINE
| ID: mdl-36786986
ABSTRACT
Metabolic reprogramming has become the new hallmark of cancer. Carbohydrate metabolism is a key component of metabolic transformations in tumors. To date, many therapeutic agents have been identified that target proteins and enzymes involved in glucose transport and metabolism, with promising results in cell culture studies and animal tumor models. In our studies, we found that the most promising among them is the glycolysis inhibitor iodoacetate. The study of this agent showed that iodoacetate in liposomal form has the best performance. With a course introduction, its antimetastatic and antitumor activity reached significant indices of growth inhibition. At the same time, liposomes with iodoacetate had an almost completely safe toxicological profile compared to the independent form and, as a result, have great potential in polychemotherapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms
/
Antineoplastic Agents
Limits:
Animals
Language:
En
Journal:
Dokl Biochem Biophys
Journal subject:
BIOFISICA
/
BIOQUIMICA
Year:
2022
Document type:
Article
Affiliation country:
RUSSIA